Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Here's Why PTC Therapeutics Fell as Much as 11.7% Today

By Maxx Chatsko - Updated Apr 22, 2019 at 1:02PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company announced the pricing of a share offering announced the day before.

What happened

Shares of PTC Therapeutics ( PTCT -4.72% ) fell nearly 12% today after the company announced the pricing of a share offering. The biopharma will offer up to 7.7 million shares of common stock at a price of $30.20 apiece. The offering will dilute the outstanding share count by approximately 15%, and investors considered the pricing a little low.

If the maximum number of shares find buyers, then PTC Therapeutics will realize gross proceeds of about $233 million. That will bolster the company's relatively comfortable cash position, which stood at $206 million at the end of September 2018.

As of 2:40 p.m. EST, the stock had settled to a 9.6% loss.

A pink declining arrow crashing through the floor of a chart on a chalkboard

Image source: Getty Images.

So what

PTC Therapeutics has three commercial products, with another about to launch. The biopharma's pipeline sports two drug candidates in each of phase 1, phase 2, and phase 3 clinical trials. There's a healthy number of preclinical and discovery-stage assets in the works, too.

All of those sales, marketing, and research and development expenses really add up. While PTC Therapeutics reported a year-over-year increase of 55% in revenue in the first nine months of 2018, the business delivered an operating loss of $70 million in both periods. A portion of that includes noncash expenses, but the company is still dependent on share offerings to fund the scale-up of its maturing business -- thus, the need for a stock offering.

Now what

The recent share offering will be the largest from PTC Therapeutics in the last two years, at least. While the offering stings existing shareholders, the biopharma will be putting the cash to good use: expanding the market presence of its commercial products, launching a new one, and developing a half-dozen other product candidates. If the business continues to grow, then one day it won't need to rely on external financing. Then again, Wall Street is increasingly worried that one of its prized drug assets may soon be obsolete, which might be another reason to bolster the cash position at this time.

Check out the latest PTC Therapeutics earnings call transcript.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

PTC Therapeutics, Inc. Stock Quote
PTC Therapeutics, Inc.
$35.36 (-4.72%) $-1.75

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/05/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.